Loading
RAD51C (DNA repair protein RAD51 homolog 3) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Breast cancer, Gastric & gastro-oesophageal junction cancer and 2 more.
Essential for the homologous recombination (HR) pathway of DNA repair. Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents. Part of the RAD51 paralog protein complexes BCDX2 and CX3 which act at different stages of the BRCA1-BRCA2-dependent HR pathway.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Olaparib. Open Targets scores its association with cancer at 0.87 (direct and indirect evidence; datatypes genetic literature 0.86, affected pathway 0.81, literature 0.97, genetic association 0.88, somatic mutation 0.96, animal model 0.25).
In plain words · RAD51C (DNA repair protein RAD51 homolog 3) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Breast cancer, Gastric & gastro-oesophageal junction cancer and 2 more.
RAD51C (DNA repair protein RAD51 homolog 3) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Breast cancer, Gastric & gastro-oesophageal junction cancer and 2 more.
Essential for the homologous recombination (HR) pathway of DNA repair. Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents.
No product in this corpus aims at RAD51C yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Germline variant: UniProt lists Fanconi anemia complementation group O (FANCO) under involvement in disease, and the record is a DNA repair gene; the medicines linked to it act through the loss (synthetic lethality) or use the variant to pick patients. HPA RAD51C: RNA low tissue specificity; no normal tissue stained high. Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Ovarian cancer, Breast cancer (all types), Gastric & gastro-oesophageal junction cancer, Prostate cancer, Skin cancer (all types)); Open Targets associates it with 9 specific cancer types at or above 0.5 (hereditary breast ovarian cancer syndrome, ovarian cancer, RAD51C-related cancer predisposition, hereditary neoplastic syndrome, ovarian carcinoma, breast carcinoma and more). (Rule 2 of scripts/fetch-target-specificity.ts.)
Sources: UniProt O43502; Human Protein Atlas RAD51C tissue; Open Targets ENSG00000108384 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Dosanjh M.K. et al, Nucleic Acids Res, 1998, "Isolation and characterization of RAD51C, a new human member of the RAD51 family of related genes". Source.
Sources: HGNC HGNC:9820 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O43502 (protein name, function text, keywords and locations (REST API)); CIViC gene RAD51C (1 evidence items, 0 assertions, 1 variants; diseases: Castration-resistant Prostate Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000108384 (association with cancer (MONDO_0004992) 0.87; per-cancer scores at or above 0.5: gastric cancer 0.61, ovarian cancer 0.83, melanoma 0.50, breast cancer 0.82 (GraphQL API, CC0))
Essential for the homologous recombination (HR) pathway of DNA repair. Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents. Part of the RAD51 paralog protein complexes BCDX2 and CX3 which act at different stages of the BRCA1-BRCA2-dependent HR pathway. Upon DNA damage, BCDX2 seems to act downstream of BRCA2 recruitment and upstream of RAD51 recruitment; CX3 seems to act downstream of RAD51 recruitment; both complexes bind predominantly to the intersection of the four duplex arms of the Holliday junction (HJ) and to junction of replication forks. The BCDX2 complex was originally reported to bind single-stranded DNA, single-stranded gaps in duplex DNA and specifically to nicks in duplex DNA. The BCDX2 subcomplex RAD51B:RAD51C exhibits single-stranded DNA-dependent ATPase activity suggesting an involvement in early stages of the HR pathway. Location: Nucleus; Cytoplasm; Cytoplasm, perinuclear region; Mitochondrion (UniProt). Locus 17q22 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
HPA RAD51C tissue · HPA RAD51C pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
It is the best population-based estimate of how much TNBC is homologous recombination deficient, shows that most of it is not germline BRCA, and argues that whole-genome sequencing at diagnosis could stratify trials and pick out the low group that needs something other than DNA-damaging chemotherapy.
It defines the gene list a TNBC germline panel should report on and shows the same genes apply in African American women, the population with the highest TNBC incidence.
This cohort underpins the guideline shift to germline BRCA1/2 testing for all TNBC patients regardless of age or family history, and it is the prevalence figure the corpus uses for germline BRCA1 in TNBC.
Query for this target: (TITLE:"RAD51C" OR ABSTRACT:"RAD51C" OR TITLE:"RAD51 paralog C" OR ABSTRACT:"RAD51 paralog C" OR TITLE:"DNA repair protein RAD51 homolog 3" OR ABSTRACT:"DNA repair protein RAD51 homolog 3" OR TITLE:"RAD51L2" OR ABSTRACT:"RAD51L2" OR TITLE:"FANCO" OR ABSTRACT:"FANCO") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RAD51C, not a curated reading list.
Shares Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing, Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer, Homologous recombination repair gene mutation in prostate cancer, CIViC.
Shares Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing, Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer, Homologous recombination repair gene mutation in prostate cancer, CIViC.
Shares Homologous recombination repair gene mutation in prostate cancer, CIViC, Gastric & gastro-oesophageal junction cancer, Ovarian cancer.
Shares Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing, Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer, Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study, Homologous recombination repair gene mutation in prostate cancer.
Shares Homologous recombination repair gene mutation in prostate cancer, CIViC, Gastric & gastro-oesophageal junction cancer, Ovarian cancer.
Shares Homologous recombination repair gene mutation in prostate cancer, CIViC, Gastric & gastro-oesophageal junction cancer, Ovarian cancer.
Shares Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study, Homologous recombination repair gene mutation in prostate cancer, Ovarian cancer, Prostate cancer.
Shares Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer, Ovarian cancer, Prostate cancer.